N
ESPR

Natixis’s Esperion Therapeutics ESPR Stock Holding History

Natixis’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-13,424
Closed -$689K – 797
2020
Q2 		$689K Buy
+13,424
New +$562K 0.01% 568
2020
Q1 		– Sell
-8,407
Closed -$503K – 753
2019
Q4 		$503K Buy
8,407
+876
+12% +$39.4K ﹤0.01% 714
2019
Q3 		$276K Sell
7,531
-14,032
-65% -$556K ﹤0.01% 744
2019
Q2 		$1M Buy
21,563
+9,095
+73% +$427K 0.01% 534
2019
Q1 		$500K Sell
12,468
-9,579
-43% -$430K ﹤0.01% 664
2018
Q4 		$1.01M Buy
22,047
+14,439
+190% +$696K 0.01% 510
2018
Q3 		$338K Sell
7,608
-436
-5% -$20K ﹤0.01% 675
2018
Q2 		$315K Sell
8,044
-835
-9% -$42.2K ﹤0.01% 755
2018
Q1 		$642K Sell
8,879
-1,198
-12% -$88K ﹤0.01% 644
2017
Q4 		$663K Buy
+10,077
New +$543K 0.01% 559

Other funds holding ESPR

BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Natixis's ESPR Position: Q3 2020 in Review

Natixis sold out of Esperion Therapeutics (ESPR) in Q3 2020, closing a stake of 13,424 shares — an estimated $689K sold.

Natixis first reported a position in ESPR in Q4 2017 and held it in 10 quarters. The position peaked at $1.01M in Q4 2018. 166 funds tracked by Wall St. Rank hold ESPR as of Q3 2020.

  • Natixis reported no remaining Esperion Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Natixis sold 13,424 Esperion Therapeutics shares in Q3 2020, an estimated $689K.
  • Natixis first reported a position in Esperion Therapeutics in Q4 2017 and held it in 10 quarters.
  • Natixis's Esperion Therapeutics position peaked at $1.01M in Q4 2018.
  • 166 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2020.

Based on Natixis's 13F filing for Q3 2020, filed 12 Nov 2020.